NRXS
NRXS
US64134X2018
Neuraxis, Inc.
Loading chart...

Company Profile

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Latest News

Related stocks

CBIO
CBIO • United States
Crescent Biopharma, Inc.
14.91 USD
553.86M USD 1Y +17.1%
CRMD
CRMD • United States
CorMedix Inc.
7.38 USD
575.23M USD 1Y -35%
MNPR
MNPR • United States
Monopar Therapeutics Inc.
78.96 USD
529.99M USD 1Y -14.8%
PBYI
PBYI • United States
Puma Biotechnology Inc
10.29 USD
531.17M USD 1Y +90.6%
OABI
OABI • United States
OmniAb, Inc.
4.79 USD
696.42M USD 1Y +166.3%
RGNX
RGNX • United States
REGENXBIO Inc.
8.07 USD
532.73M USD 1Y -33.8%
ANNX
ANNX • United States
Annexon, Inc.
4.02 USD
762.11M USD 1Y +27%
SGP
SGP • United States
SpyGlass Pharma, Inc.
24.92 USD
833.52M USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
92.1% p.a.
Max Drawdown (3Y)
-57.9%
Sharpe Ratio (3Y)
0.23
Beta Factor
1.36
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende